Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
- PMID: 28676480
- PMCID: PMC5642790
- DOI: 10.1136/bmjopen-2016-015735
Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
Abstract
Objective: Proton pump inhibitors (PPIs) are widely used, and their use is associated with increased risk of adverse events. However, whether PPI use is associated with excess risk of death is unknown. We aimed to examine the association between PPI use and risk of all-cause mortality.
Design: Longitudinal observational cohort study.
Setting: US Department of Veterans Affairs.
Participants: Primary cohort of new users of PPI or histamine H2 receptor antagonists (H2 blockers) (n=349 312); additional cohorts included PPI versus no PPI (n=3 288 092) and PPI versus no PPI and no H2 blockers (n=2 887 030).
Main outcome measures: Risk of death.
Results: Over a median follow-up of 5.71 years (IQR 5.11-6.37), PPI use was associated with increased risk of death compared with H2 blockers use (HR 1.25, CI 1.23 to 1.28). Risk of death associated with PPI use was higher in analyses adjusted for high-dimensional propensity score (HR 1.16, CI 1.13 to 1.18), in two-stage residual inclusion estimation (HR 1.21, CI 1.16 to 1.26) and in 1:1 time-dependent propensity score-matched cohort (HR 1.34, CI 1.29 to 1.39). The risk of death was increased when considering PPI use versus no PPI (HR 1.15, CI 1.14 to 1.15), and PPI use versus no PPI and no H2 blockers (HR 1.23, CI 1.22 to 1.24). Risk of death associated with PPI use was increased among participants without gastrointestinal conditions: PPI versus H2 blockers (HR 1.24, CI 1.21 to 1.27), PPI use versus no PPI (HR 1.19, CI 1.18 to 1.20) and PPI use versus no PPI and no H2 blockers (HR 1.22, CI 1.21 to 1.23). Among new PPI users, there was a graded association between the duration of exposure and the risk of death.
Conclusions: The results suggest excess risk of death among PPI users; risk is also increased among those without gastrointestinal conditions and with prolonged duration of use. Limiting PPI use and duration to instances where it is medically indicated may be warranted.
Keywords: Adverse events; CLINICAL PHARMACOLOGY; EPIDEMIOLOGY; Gastroduodenal disease; Health & safety; PUBLIC HEALTH.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
The Verdict: Proton Pump Inhibitors have been found guilty of causing death. Any objections?Turk J Gastroenterol. 2017 Nov;28(6):544-545. doi: 10.5152/tjg.2017.111017. Epub 2017 Oct 30. Turk J Gastroenterol. 2017. PMID: 29082886 No abstract available.
Similar articles
-
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.J Am Soc Nephrol. 2016 Oct;27(10):3153-3163. doi: 10.1681/ASN.2015121377. Epub 2016 Apr 14. J Am Soc Nephrol. 2016. PMID: 27080976 Free PMC article.
-
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.JAMA Intern Med. 2016 Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193. JAMA Intern Med. 2016. PMID: 26752337 Free PMC article.
-
Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.Aliment Pharmacol Ther. 2012 Nov;36(9):866-74. doi: 10.1111/apt.12045. Aliment Pharmacol Ther. 2012. PMID: 22966967 Free PMC article.
-
Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.Dig Dis Sci. 2017 Oct;62(10):2821-2827. doi: 10.1007/s10620-017-4725-5. Epub 2017 Aug 23. Dig Dis Sci. 2017. PMID: 28836158 Review.
-
Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: A meta-analysis.World J Gastroenterol. 2015 May 28;21(20):6341-51. doi: 10.3748/wjg.v21.i20.6341. World J Gastroenterol. 2015. PMID: 26034370 Free PMC article. Review.
Cited by
-
Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis.Biomedicines. 2024 Jun 25;12(7):1414. doi: 10.3390/biomedicines12071414. Biomedicines. 2024. PMID: 39061988 Free PMC article. Review.
-
Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B12 Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.Int J Mol Sci. 2024 Jul 2;25(13):7286. doi: 10.3390/ijms25137286. Int J Mol Sci. 2024. PMID: 39000391 Free PMC article.
-
Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence.J Clin Med. 2024 Mar 28;13(7):1970. doi: 10.3390/jcm13071970. J Clin Med. 2024. PMID: 38610738 Free PMC article. Review.
-
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study.Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):413-419. doi: 10.1093/ehjcvp/pvae020. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38486369 Free PMC article.
-
Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study.Crit Care Med. 2024 Feb 1;52(2):190-199. doi: 10.1097/CCM.0000000000006104. Epub 2024 Jan 19. Crit Care Med. 2024. PMID: 38240505 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources